We encourage you to discover our newest EAACI Knowledge Hub content: “Drug Hypersensitivity Module"
The aim of the module is to provide information about basic and recent advancements in diagnosis and management of hypersensitivity reactions due to biologicals in order to harmonize the clinical approach among clinicians and enhance their information by looking at the topic from different angles.
This educational tool comprises three modules of brief lectures on diagnosis and management of hypersensitivity reactions due to biologicals. In each module, three well-known speakers give updated information and share their individual expertise with audience.
María José Torres Jaén
Hospital Regional Universitario de Málaga, Spain
EAACI Secretary General
Aslı Akkor
Istanbul Faculty of Medicine
Istanbul University
EAACI Knowledge Hub Deputy Editor
The first module focuses on the burden of hypersensitivity reactions to biologicals. The aim of this module is to introduce the broad spectrum of indications of biologicals and to describe diverse hypersensitivity reactions as well as the conditions such as cytokine release syndrome, infusion reactions that resemble and/or accompany hypersensitivity in real practice. Furthermore, the real incidence of hypersensitivity reactions is presented to show the expected future burden of such reactions.
Biological agents: Friend or foe
Ricardo Madrigal Burgaleta
London, United Kingdom
Epidemiology of hypersensitivity reactions to biologics
Luciana Kase Tanno
Sao Paulo, Brazil
How mislabeling biological hypersensitivity influences real incidence
Gülfem Elif Çelik
Ankara, Türkiye
The second module focuses on pitfalls in diagnosis of HRs due to biologicals. The mechanisms beneath these reactions, the risk factors for these reactions and potential biomarkers for stratifying risky populations are outlined.
Mechanisms of hypersensitivity reactions to biologicals
Mariana Castells
Boston, USA
Risk factors for suffering hypersensitivity reactions to biologicals
Knut Brockow
Munich, Germany
Biomarkers of hypersensitivity reactions to biologicals
Cristobalina Mayorga
Malaga, Spain
Finally, the third module describes the recent advancements in in vivo and in vitrodiagnosis and management of hypersensitivity reactions due to biologicals.
Biologicals are now becoming main therapeutic options in various clinical areas including cancer, inflammatory diseases and even allergy and asthma. Unfortunately, hypersensitivity reactions caused by biologicals are arising in parallel to their increased usage. The burden of these reactions is expected to be more significant in future considering the increased frequency observed since introduction of these drugs. Novel drugs while saving lives are becoming potential culprits of life-threatening reactions such as anaphylaxis or toxic epidermal necrolysis.
In vivo diagnosis of hypersensitivity reactions to biologicals
María José Torres Jaén
Malaga, Spain
In vitro diagnosis of hypersensitivity reactions to biologicals
Andrea Matucci
Firenze, Italy
Management of hypersensitivity reactions to biologicals
Leticia de las Vecillas
Madrid, Spain
Biologicals are widely used as therapeutic weapons to hit the desired target in the management of chronic progressing diseases like cancer and inflammatory diseases. Meanwhile, cases of hypersensitivity reactions due to these drugs are increasingly reported worldwide and their management strategies are becoming significant guides for other clinicians in various fields who witness these reactions.
This educational tool comprises brief lectures given by experts in drug allergy which can give accurate knowledge on diagnosis and management of these reactions. Clinicians who are dealing with or witnessing hypersensitivity reactions due to biologicals will find the necessary information for practical care and improve their knowledge.
This educational tool with its content represents a significant source of knowledge and is expected to fill the gap in this field to some extent.
By attending the modules, students, allergy trainees, allergists, all HCPs with the chance to come across drug allergy, and also academicians can have the benefit of updating their knowledge in drug allergy.
Live Q&As with the speakers will be scheduled and announced in the following weeks, and eventually you will have the possibility to gain CME accreditation by watching the module and taking the assessments!
Head over to hub.eaaci.org to discover the new EAACI Drug Allergy module!
Watch an introduction to this exciting module by Prof. Asli Gelincik Akkor and Prof. Maria Torres!
No comments:
Post a Comment